Literature DB >> 18762512

Retinoblastoma: one world, one vision.

Carlos Rodriguez-Galindo1, Mathew W Wilson, Guillermo Chantada, Ligia Fu, Ibrahim Qaddoumi, Célia Antoneli, Carlos Leal-Leal, Tarun Sharma, Margarita Barnoya, Sidnei Epelman, Louis Pizzarello, Javier R Kane, Ray Barfield, Thomas E Merchant, Leslie L Robison, A Linn Murphree, Patricia Chevez-Barrios, Michael A Dyer, Joan O'Brien, Raul C Ribeiro, John Hungerford, Eugene M Helveston, Barrett G Haik, Judith Wilimas.   

Abstract

Retinoblastoma is curable when diagnosed early and treated appropriately; however, the prognosis is dismal when the basic elements of diagnosis and treatment are lacking. In developing countries, poor education, lower socioeconomic conditions, and inefficient health care systems result in delayed diagnosis and suboptimal care. Furthermore, the complexity of multidisciplinary care required is seldom possible. Whereas ocular salvage is a priority in the Western world, death from retinoblastoma is still a major problem in developing countries. To bring the 2 ends of this spectrum together and provide a forum for discussion, the "One World, One Vision" symposium was organized, at which clinicians and researchers from various cultural, geographic, and socioeconomic backgrounds converged to discuss their experiences. Strategies for early diagnosis in developing countries were discussed. Elements of the development of retinoblastoma centers in developing countries were discussed, and examples of successful programs were highlighted. An important component in this process is twinning between centers in developing countries and mentor institutions in high-income countries. Global initiatives by nongovernmental organizations such as the International Network for Cancer Treatment and Research, Orbis International, and the International Agency for Prevention of Blindness were presented. Treatment of retinoblastoma in developing countries remains a challenge; however, it is possible to coordinate efforts at multiple levels, including public administrations and nonprofit organizations, to improve the diagnosis and treatment of retinoblastoma and to improve the outcome for these children.

Entities:  

Mesh:

Year:  2008        PMID: 18762512      PMCID: PMC2844325          DOI: 10.1542/peds.2008-0518

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  26 in total

1.  Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area.

Authors:  Scott C Howard; Marcia Pedrosa; Mecneide Lins; Arli Pedrosa; Ching-Hon Pui; Raul C Ribeiro; Francisco Pedrosa
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

Review 2.  VISION 2020: The Right to Sight: a global initiative to eliminate avoidable blindness.

Authors:  Louis Pizzarello; Adenike Abiose; Timothy Ffytche; Rainaldo Duerksen; R Thulasiraj; Hugh Taylor; Hannah Faal; Gullapali Rao; Ivo Kocur; Serge Resnikoff
Journal:  Arch Ophthalmol       Date:  2004-04

3.  Results of a stage-based protocol for the treatment of retinoblastoma.

Authors:  E Schvartzman; G Chantada; A Fandiño; M T de Dávila; E Raslawski; J Manzitti
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Retinoblastoma with low risk for extraocular relapse.

Authors:  G L Chantada; M T de Dávila; A Fandiño; J Manzitti; E Raslawski; S Casak; E Schvartzman
Journal:  Ophthalmic Genet       Date:  1999-09       Impact factor: 1.803

5.  Extraocular retinoblastoma: a 13-year experience.

Authors:  Célia Beatriz Gianotti Antoneli; Flávio Steinhorst; Karina de Cássia Braga Ribeiro; Paulo Eduardo R S Novaes; Martha M M Chojniak; Victor Arias; Beatriz de Camargo
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

6.  A multicentre report from the Mexican Retinoblastoma Group.

Authors:  C Leal-Leal; M Flores-Rojo; A Medina-Sansón; F Cerecedo-Díaz; S Sánchez-Félix; O González-Ramella; F Pérez-Pérez; R Gómez-Martínez; A Quero-Hernández; E Altamirano-Alvarez; F Alejo-González; J Figueroa-Carbajal; A Ellis-Irigoyen; I Tejocote-Romero; R Cervantes-Paz; F Pantoja-Guillén; L Vega-Vega; F Carrete-Ramírez
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

7.  Results of a prospective study for the treatment of retinoblastoma.

Authors:  Guillermo Chantada; Adriana Fandiño; María T G Dávila; Julio Manzitti; Elsa Raslawski; Sandra Casak; Enrique Schvartzman
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

8.  Team management, twinning, and telemedicine in retinoblastoma: a 3-tier approach implemented in the first eye salvage program in Jordan.

Authors:  Ibrahim Qaddoumi; Ibrahim Nawaiseh; Mustafa Mehyar; Bassem Razzouk; Barrett G Haik; Saamir Kharma; Imad Jaradat; Carlos Rodriguez-Galindo; Matthew W Wilson
Journal:  Pediatr Blood Cancer       Date:  2008-08       Impact factor: 3.167

9.  Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma.

Authors:  S Krishnakumar; K Mallikarjuna; N Desai; A Muthialu; N Venkatesan; A Sundaram; V Khetan; M P Shanmugam
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

10.  Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center.

Authors:  Jyotirmay Biswas; Dipankar Das; S Krishnakumar; Mahesh P Shanmugam
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2003 Sep-Oct       Impact factor: 1.402

View more
  36 in total

1.  Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

Authors:  Rachel C Brennan; Sara Federico; Cori Bradley; Jiakun Zhang; Jacqueline Flores-Otero; Matthew Wilson; Clinton Stewart; Fangyi Zhu; Kip Guy; Michael A Dyer
Journal:  Cancer Res       Date:  2011-04-22       Impact factor: 12.701

2.  Extraocular retinoblastoma in Indian children: clinical, imaging and histopathological features.

Authors:  Sumita Sethi; Neelam Pushker; Seema Kashyap; Sanjay Sharma; Mridula Mehta; Sameer Bakhshi; Saurbhi Khurana; Supriyo Ghose
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

3.  Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.

Authors:  Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-07-24       Impact factor: 5.258

4.  Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Cancer Nanotechnol       Date:  2010-10-25

5.  Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma.

Authors:  Aman Khurana; Christina A Eisenhut; Wenshuai Wan; Katayoon B Ebrahimi; Chirag Patel; Joan M O'Brien; Kristen Yeom; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2012-11-18       Impact factor: 5.315

Review 6.  Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.

Authors:  C L Shields; E M Fulco; J D Arias; C Alarcon; M Pellegrini; P Rishi; S Kaliki; C G Bianciotto; J A Shields
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

7.  Epidemiology and Rb1 gene of retinoblastoma.

Authors:  Jun Yun; Yang Li; Chang-Tai Xu; Bo-Rong Pan
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

8.  Cotylenin A inhibits cell proliferation and induces apoptosis and PAX6 mRNA transcripts in retinoblastoma cell lines.

Authors:  Yoshiko Kashiwagi; Nobuo Kato; Takeshi Sassa; Koichi Nishitsuka; Teiko Yamamoto; Hiroshi Takamura; Hidetoshi Yamashita
Journal:  Mol Vis       Date:  2010-06-04       Impact factor: 2.367

9.  "Retinoblastoma survival disparity": The expanding horizon in developing countries.

Authors:  Masood Naseripour
Journal:  Saudi J Ophthalmol       Date:  2012-02-18

10.  Development of retinoblastoma programs in Central America.

Authors:  Judith A Wilimas; Matthew W Wilson; Barrett G Haik; Margarita Barnoya; Ligia Fu; Mauricio Castellanos; Miguel Bonilla; Blanca Phillips; Eugene M Helveston; Sandra Luna-Fineman; Raul Ribeiro; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.